Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Natural History to Assess Disease in Patients With MPS IIIC (C-RARE)

15 juli 2026 bijgewerkt door: Phoenix Nest

Observational Study to Assess Disease Symptoms and Progression in Participants With Sanfilippo Syndrome Type C (Mucopolysaccharidosis Type III [MPS III] C)

This is a REMOTE prospective observational study of participants with MPS IIIC.

No investigational medicinal product will be administered as part of this study.

Patients functional abilities will be captured using video recordings taken by patients legal representative or caregiver using a dedicated clinical video application downloaded from the internet onto a smartphone. The video application is called C-RARE.

Electronic observer-reported outcome (ObsRO) questionnaires will be completed by the legal representatives or caregivers via C-RARE.

The study will last two years with videos and questionnaires taken every 6 months for a total of 5 time points. Data will then be reviewed and measured for functional change using a scoring scale designed for the use of this study.

Studie Overzicht

Toestand

Nog niet aan het werven

Gedetailleerde beschrijving

The study will be conducted remotely; no in-person visits are required. Approximately 35 participants with MPS IIIC will be enrolled in the study through a study site in the United States of America (USA). Enrollment of the first 25 participants with age ≤10 years will help ensure that the data collected from these younger participants will provide a better understanding of the early phase of the disease that may be relevant for future drug development. The remaining 10 participants will be between 11 to 25 years of age. The cutoff for the study is 25 years old. Participants speaking either Spanish, Portuguese, German, French or English may enroll in the study.

At Screening (Visit 1), the site coordinator based at UT Southwestern will review the laboratory report with a confirmed diagnosis of Hgsnat-deficiency MPS IIIC and a mutational analysis report demonstrating homozygous or compound heterozygous, pathogenic, and/or potentially pathogenic variants in the Hgsnat gene to assess the eligibility of the participants. After confirming diagnosis by the site coordinator, the caregiver or legal representative(s) will read and sign the informed consent form electronically, and when possible, the participant will provide adult or pediatric assent electronically.

At Baseline (Visit 2), the legal representative(s) or caregiver will be asked to complete electronic demographics and medical record questionnaire via the C-RARE App.

At Baseline (Visit 2) and at 6-month intervals (from Visit 3 through the end of the study), the legal representative(s) or caregiver will be asked to complete questionnaires and record home video assessments using a dedicated study app called C-RARE. Functional and cognitive abilities will be captured in the home environment by video and PEDI-CAT, an electronic a caregiver reported outcome assessment.

The legal representative(s) or caregiver will be provided with a C-RARE kit (via mailing), which includes a manual and props, as well as training for using the app. Baseline at-home visit (demographics, medical/surgical history, concomitant medications/therapy history, video and PEDI-CAT assessment, and ObsRO) should be completed at Visit 2. At-home Visit 3 to Visit 6 (video, PEDI-CAT assessment, and ObsRO) should be completed within a 14-day period for each visit. The legal representative(s) or caregiver will be provided with the timeline for each visit.

The study population will include participants with a confirmed diagnosis of MPS IIIC. Participants will be recruited for approximately 3 months by patient organizations. The patient organizations will provide participants with details of the site coordinator at UTSW. Participant-level data will be obtained through C-RARE app and PEDI-CAT.

Studietype

Observationeel

Inschrijving (Geschat)

35

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Kind
  • Volwassen

Accepteert gezonde vrijwilligers

Nee

Bemonsteringsmethode

Niet-waarschijnlijkheidssteekproef

Studie Bevolking

The study population will include participants with confirmed diagnosis of MPS IIIC. Participants will be recruited for approximately 3 months by patient organizations. The patient organizations will provide participants with details of the site coordinator at University of Texas Southwestern (UTSW).

Beschrijving

Inclusion Criteria:

  • 1. ≥1 year and ≤ 25 years of age 2. Confirmed diagnosis of MPS IIIC by all of the following:

    1. Deficiency in the Hgsnat enzyme activity
    2. Genetic analysis demonstrating homozygous or compound heterozygous, pathogenic, and/or potentially pathogenic variants in the Hgsnat gene
    3. Signs/symptoms consistent with MPS IIIC, or individuals who have not presented with signs/symptoms of disease but meet inclusion criteria 2a and 2b 3. Electronic informed consent from legal representative(s) or caregivers and when possible, pediatric or adult assent from the participant 4. One of the legal representative(s) or the caregivers is willing to perform at home visits and assessments per instruction 5. Ability to comply with protocol requirements, in the opinion of the Investigator 6. Able to take food or liquid by mouth, able to walk with or without assistance 7. Participants must have health insurance 8. Caregiver willing and able to comply with protocol requirements, including performing at-home visits and assessments 9. Participants must have smart phone or tablet and reliable internet connection 10. Have one of these languages as their first language: English, Spanish, French, German or Portuguese

      Exclusion Criteria:

      1. Have received prior gene therapy or ERT for the treatment of MPS IIIC ever or any other investigational drug for any reason within 30 days prior to the Screening visit (Visit 1)
      2. Have concomitant illness or medical condition that, in the opinion of the Investigator, might compromise the participant's ability to comply with protocol requirements or the participant's wellbeing or safety, or the interpretability of the participant's clinical data

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Daily living functions captured by video
Tijdsspanne: Baseline to up to 2 years with 6-month time points.
Ability to perform activities of daily living.
Baseline to up to 2 years with 6-month time points.
Expressive and receptive language assessed by standard questionnaires
Tijdsspanne: Baseline to up to 2 years with 6-month time points.
Ability to understand, comprehend and respond to communication.
Baseline to up to 2 years with 6-month time points.
Speech as assessed by standard questionnaires
Tijdsspanne: Baseline to up to 2 years; with 6-month time points.
Analysis of speech quality.
Baseline to up to 2 years; with 6-month time points.
Behavior as assessed by ability to perform daily functions as captured by video
Tijdsspanne: Baseline to up to 2 years with 6-month time points.
Quality of behavior as defined by ability to perform defined functions
Baseline to up to 2 years with 6-month time points.
Mobility as assessed by video and standard questionnaires
Tijdsspanne: Baseline up to 2 years with 6-month time points.
Assessment of fine and gross motor abilities
Baseline up to 2 years with 6-month time points.

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
What Matters Most
Tijdsspanne: Baseline up to 2years with 6-month time points.
Questionnaire asking caregiver to rank skills from most important to least
Baseline up to 2years with 6-month time points.
Assessment of Behavioral Changes in Sanfilippo (ABCS)
Tijdsspanne: Baseline up to 2 years with 6-month time points.
Questionnaire asking families to rank changes in patients behavior over time.
Baseline up to 2 years with 6-month time points.
PEDI-CAT standard questionnaire
Tijdsspanne: Baseline up to 2 years with 6-month time points.
Observer reporter cognitive outcome questionnaire
Baseline up to 2 years with 6-month time points.

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

1 november 2026

Primaire voltooiing (Geschat)

1 november 2028

Studie voltooiing (Geschat)

1 februari 2029

Studieregistratiedata

Eerst ingediend

15 juni 2026

Eerst ingediend dat voldeed aan de QC-criteria

15 juli 2026

Eerst geplaatst (Werkelijk)

17 juli 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

17 juli 2026

Laatste update ingediend die voldeed aan QC-criteria

15 juli 2026

Laatst geverifieerd

1 juli 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Results of study findings will be published.

IPD-tijdsbestek voor delen

2030, indefinitely.

IPD-toegangscriteria voor delen

Once published anyone can access study results online.

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP
  • ICF

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren